Abstracts tagged "giant cell arteritis and vasculitis"

Abstract Number: 2358 • 2012 ACR/ARHP Annual Meeting
Large Vessel Giant Cell Arteritis: A Cohort Study
Francesco Muratore¹, Tanaz A. Kermani², Cynthia S. Crowson³, Abigail B. Green³, Eric L. Matteson⁴ and Kenneth J. Warrington⁵, ¹Rheumatology, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ²Rheumatology, University of California Los Angeles, Los Angeles, CA, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: A subset of patients with giant cell arteritis (GCA) has large vessel (LV) involvement. We sought to identify baseline variables that distinguish patients with…
Abstract Number: 2363 • 2012 ACR/ARHP Annual Meeting
Assessment of Disease Activity in Large Vessel Vasculitis: Initial Results of an International Delphi Exercise
Sibel Z. Aydin¹, Haner Direskeneli², Eric L. Matteson³ and Peter A. Merkel⁴, ¹Unit of Rheumatology, Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey, ²Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Assessment of disease activity in large vessel vasculitis (LVV) is challenging. The lack of specific, validated outcome measurements for both Takayasu’s (TAK) and giant…
Abstract Number: 855 • 2012 ACR/ARHP Annual Meeting
Identification of a Burkholderia-Like Strain From Temporal Arteries of Subjects with Giant Cell Arteritis
Curry L. Koening¹, Bradley J. Katz², Jose Hernandez-Rodriguez³, Marc Corbera-Bellalta⁴, Maria C. Cid⁵, Herbert P. Schweizer⁶, Dean Li², Jerry Kaplan², Gary S. Hoffman⁷ and Ivana De Domenico⁸, ¹Internal Medicine, Salt Lake City Veterans Administration, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁴Systemic Autoimmune Diseases, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁵Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁶Colorado State University, Fort Collins, CO, ⁷Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, ⁸Internal Medicine-Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: Giant cell arteritis (GCA) is a granulomatous vasculitis of large- and medium-sized arteries. An infectious organism has been hypothesized to cause GCA. We used…
Abstract Number: 857 • 2012 ACR/ARHP Annual Meeting
Impairment of the Inhibitory PD-1-PD-L1 Axis in Giant Cell Arteritis (GCA)
Mazen Nasrallah¹, Augusto Vaglio², Shalini Mohan¹, Bjorn Hartmann³, Joyce Liao⁴, Kenneth J. Warrington⁵, Jorg J. Goronzy³ and Cornelia M. Weyand⁶, ¹Medicine: Immunology and Rheumatology, Stanford University, Stanford, CA, ²Unit of Nephrology, University Hospital of Parma, Parma, Italy, ³Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Byers Eye Institute at Stanford, Stanford University, Palo Alto, CA, ⁵Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁶Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Giant cell arteritis (GCA) is an autoimmune syndrome characterized by granuloma formation in the media of medium and large arteries. In a healthy immune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].